What is your radiotherapy approach for a patient with ES-SCLC (diagnosis 1 year ago) with extensive extracranial metastases s/p chemotherapy with stable disease who now presents with multiple (<5) brain metastases?

Very new phase III randomized data presented at ASTRO 2026 compared SRS with hippocampal-avoidance WBRT plus memantine. ASTRO reports a median OS of 17 months with SRS versus 9 months with HA-WBRT, although survival was a secondary endpoint, and the full peer-reviewed dataset will be important for i...